Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | HS-10365 |
Synonyms | |
Therapy Description |
HS-10365 selectively inhibits RET, potentially resulting in antitumor activity (Cancer Res (2023) 83 (8_Supplement): CT201). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
HS-10365 | HS 10365|HS10365 | RET Inhibitor 53 | HS-10365 selectively inhibits RET, potentially resulting in antitumor activity (Cancer Res (2023) 83 (8_Supplement): CT201). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
RET fusion | lung non-small cell carcinoma | predicted - sensitive | HS-10365 | Phase I | Actionable | In a Phase I trial, HS-10365 treatment demonstrated safety and resulted in a response rate of 70% (21/30) and a disease control rate of 96.7% (29/30) in patients with non-small cell lung cancer harboring RET fusions (Cancer Res (2023) 83 (8_Supplement): CT201; NCT05207787). | detail... |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|